A Look At Coloplast (CPSE:COLO B) Valuation After Recent Share Price Weakness

Recent share performance and valuation context Coloplast (CPSE:COLO B) has drawn investor attention after a series of weaker share returns, including a 10.7% decline over the past month and a 17.5% ...

CLPBY or PEN: Which Is the Better Value Stock Right Now?

But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look ...
Nasdaq

Coloplast A (XTRA:CBHD) Price Target Decreased by 11.71% to 77.93

The average one-year price target for Coloplast A (XTRA:CBHD) has been revised to 77,93 € / share. This is a decrease of 11.71% from the prior estimate of 88,27 € dated February 3, 2026. The price ...
Seeking Alpha

Coloplast: Finally Getting Buyable

Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, ...
Seeking Alpha

Coloplast: Cheaper Than In The Past, But Not Yet A Bargain

Coloplast's stock price has declined by 25% since April 2023, making it more attractive but still overvalued based on fundamentals and valuation multiples. Recent quarterly results show revenue growth ...
Fintel on MSN

Coloplast A (CLPBF) price target decreased by 11.54% to 92.23

The average one-year price target for Coloplast A (OTCPK:CLPBF) has been revised to $92.23 / share. This is a decrease of 11.54% from the prior estimate of $104.27 dated February 3, 2026. The price ...
manilatimes

Coloplast A/S CEO Kristian Villumsen steps down as of today

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...
MM&M

Coloplast buys up fish skin wound care biotech Kerecis for $1.3B

Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...
Morningstar

Coloplast's Strength in Innovation Fortifies Its Narrow Moat

Coloplast historically has introduced consistent innovation in its ostomy-care products, including different types of adhesives, one- and two-piece devices, and irrigation systems. Finally, we note ...

Coloplast A/S - Updated Financial Calendar 2025-26

Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General ...
Reuters

Coloplast buys fish skin woundcare firm for up to $1.3 billion

COPENHAGEN, July 7 (Reuters) - Coloplast (COLOb.CO), opens new tab has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up ...